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The entorhinal cortex (EC) is one of the earliest
affected, most vulnerable brain regions in Alz-
heimer’s disease (AD), which is associated with
amyloid-b (Ab) accumulation in many brain areas.
Selective overexpression of mutant amyloid precur-
sor protein (APP) predominantly in layer II/III neurons
of the EC caused cognitive and behavioral abnormal-
ities characteristic of mouse models with wide-
spread neuronal APP overexpression, including
hyperactivity, disinhibition, and spatial learning and
memory deficits. APP/Ab overexpression in the EC
elicited abnormalities in synaptic functions and
activity-related molecules in the dentate gyrus and
CA1 and epileptiform activity in parietal cortex.
Soluble Ab was observed in the dentate gyrus, and
Ab deposits in the hippocampus were localized to
perforant pathway terminal fields. Thus, APP/Ab
expression in EC neurons causes transsynaptic defi-
cits that could initiate the cortical-hippocampal
network dysfunction in mouse models and human
patients with AD.
INTRODUCTION
Alzheimer’s disease (AD) is characterized by progressive
memory impairments (Blennow et al., 2006). Since encoding of
various forms of memory requires an intact entorhinal-hippo-
campal circuit (Eichenbaum and Lipton, 2008; Squire et al.,
2004), it is not surprising that this network is severely affected
by AD. Neurons in superficial layers of the entorhinal cortex
(EC) form synapses via the perforant pathway in all hippocampal
subregions, including the dentate gyrus (DG), CA3, CA1, and
subiculum, with the largest projection to the granule cells
(GCs) of the DG (van Groen et al., 2003; van Strien et al.,
2009). In mice, DGGCs receive afferent input primarily from layer
II neurons of the EC; projections toCA3 andCA1 originatemostly428 Neuron 68, 428–441, November 4, 2010 ª2010 Elsevier Inc.from layer III (van Groen et al., 2003; van Strien et al., 2009).
Synaptic connections between mossy fibers of DG GCs and
CA3 neurons and Schaffer collaterals from CA3 to CA1 neurons
complete the forward hippocampal polysynaptic circuit.
In the entorhinal-hippocampal network, the EC is a particularly
early target in AD. Significant loss of neurons in EC layer II occurs
in the beginning stages of AD (Go´mez-Isla et al., 1996). Neurofi-
brillary tangles (NFTs), a hallmark of AD, are seen primarily in the
EC in mild AD and ‘‘spread’’ to the hippocampus and other
cortical areas as the disease progresses (Braak and Braak,
1991). Structural and functional imaging studies also show early,
selective atrophy and hypometabolism in the EC of patients with
mild cognitive impairment or early-stage AD (Masdeu et al.,
2005; Wu and Small, 2006).
Amyloid-b (Ab) peptides generated from amyloid precursor
protein (APP) by proteolytic cleavage likely play a causal role in
AD pathogenesis (Tanzi and Bertram, 2005; Walsh and Selkoe,
2004). Although the precise mechanisms of Ab toxicity are
unclear, oligomeric forms of Ab may contribute to cognitive
decline by altering synaptic structure and function (Palop and
Mucke, 2010; Selkoe, 2008; Shankar et al., 2008). Transgenic
mouse models that overexpress mutant APP and produce
high levels of Ab show amyloid plaque deposition, synaptic defi-
cits, learning and memory impairments, and other behavioral
abnormalities (Games et al., 1995; Go¨tz et al., 2004; Hsia et al.,
1999; Hsiao et al., 1996; Kobayashi andChen, 2005). Pathogenic
Ab assemblies elicit aberrant excitatory activity in cortical-hippo-
campal networks and compensatory responses that are particu-
larly evident in the DG (Palop et al., 2003, 2007).
It is unclear which brain regions or cell types are first affected
by APP/Ab to ultimately elicit network dysfunction. AD may
spread through anatomically and functionally connected brain
regions (Braak and Braak, 1991; Braak et al., 2006; Buckner
et al., 2005), perhaps by a prion-like mechanism (Eisele et al.,
2009; Frost and Diamond, 2010). In AD patients, the EC is an
early target and could be the region fromwhich AD invades other
brain regions. Neuronal alterations starting in the EC could
propagate throughout EC-hippocampal-cortical networks. It
has been hypothesized that AD originates in the EC because
APP expression was higher in EC layer II neurons than in other
Figure 1. Restricted Cortical Expression of Mutant APP in EC-APP
Mice
(A) Transgenes used to generate tTA-EC and tet-APP mouse lines. When
crossed, mice carrying both transgenes expressed mutant APP primarily in
the EC.
(B and C) Representative images of coronal (B) and horizontal (C)
brain sections from EC-APP mice stained for chimeric human/mouse APP
(h/mAPP) with anti-human Ab antibody 6E10. Prominent APP expression
was observed in medial EC and in pre- and parasubiculum (PS). Hippocampal
APP labeling was faint in scattered cells of CA regions.
(D) Higher magnification images of EC and DG in an EC-APP mouse show
neuronal expression of APP predominantly in superficial layers of the EC. No
transgene expression was observed in the granular cell layer (gcl) of the DG;
scattered APP-positive cells were seen in the hilus.
(E and F) Relative APP levels in different brain regions of EC-APP mice were
determined by western blotting (E) and quantified by densitometry (F). GAPDH
served as a loading control. EC had the highest APP levels, followed by RC,
where APP levels were less than 40% of those in EC. Values are mean ± SEM.
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Transsynaptic Effects of APP/Abcortical areas in cognitively intact people (Roberts et al., 1993);
levels further increased in early-stage AD but declined in late
stages. However, more recent studies have not found higher
APP levels in EC neurons of cognitively intact individuals or
differences in expression in patients with mild to late-stage AD
(Liang et al., 2007, 2008).
Given its various effects on synaptic function (Palop and
Mucke, 2010), Ab could be the key mediator of the proposed
transsynaptic (i.e., across a synapse) progression of AD. In
this study, we determined whether production of human Ab
by EC neurons can elicit AD-like behavioral deficits and
cortical-hippocampal network dysfunction by using mice with
transgene-derived APP expression primarily in neurons of the
superficial layers of the EC and the pre/parasubiculum. These
mice exhibited disinhibition, hyperactivity, and age-related
cognitive deficits in spatial learning and memory tasks. Similar
behavioral phenotypes have been described in transgenic
mice with widespread neuronal expression of APP/Ab (Cheng
et al., 2007; Chin et al., 2005; Go¨tz et al., 2004; Kobayashi
and Chen, 2005; Palop et al., 2003). Soluble Ab levels were
high in the DG of young mice with APP/Ab expression in EC
neurons, suggesting presynaptic synthesis and/or release of
Ab. Ab deposits in the hippocampus of older mice were mostly
seen in perforant pathway terminal fields. Finally, selective over-
expression of APP/Ab in EC neurons also increased cortical
network excitability, synaptic loss in the outer molecular layer
of the DG, and alterations in synaptic-activity-related molecules
in GCs of the DG that typically reflect such aberrant network
activity.
RESULTS
Expression of APP in the EC of Neuropsin-tTA/Tet-APP
Doubly Transgenic Mice
To producemice with regionally selective overexpression of APP
with familial AD mutations, we bred neuropsin-tTA (Yasuda and
Mayford, 2006) and tet-APP mice (Jankowsky et al., 2005)
(Figure 1A). The tet-APP transgene encodes a chimeric mouse
APP with a humanized Ab domain. Mice were not treated with
doxycycline, allowing transactivation of tet-APP expression by
tTA. Offspring with both transgenes (EC-APP mice) expressed
mutant APP primarily in the parahippocampal cortex, including
the medial EC and pre/parasubiculum (Figures 1B–1D). This
pattern is in stark contrast to the spatially generalized expression
pattern of APP in other APP transgenic lines, such as the human
APP (hAPP) transgenic line J20 (Figures S1A and S1B), and
similar to that of other tet-regulatable transgenes after crosses
with the neuropsin-tTA line (Yasuda and Mayford, 2006).
However, we observed some transgene expression in the lateral
EC and scattered cells with faint expression in superficial layers
of other cortical regions and area CA of the hippocampus
(Figures 1B–1D and S2). No mutant APP was detected in NTG
or singly tTA transgenic mice, and only very low levels of mutant
APP were detected in the CA region of tet-APP singly transgenic
mice, suggestingminimal ‘‘leakiness’’ of transgene expression in
the absence of tTA (Figures S3A and S3B). Cells expressing
mutant APP in the EC were mostly layer II or III neurons
(Figure 1D, middle). No mutant APP was detected in GCs ofthe DG, although some scattered APP-positive cells were seen
in the hilus (Figure 1D, right).
Measurement of mutant APP levels in microdissected
brain regions by western blotting confirmed the immunohisto-
chemical analyses. The EC had the highest level of full-
lengthmutant APP; levels in the DG (13%) andCA (25%) (Figures
1E and 1F) were lower and similar to the ‘‘leaky’’ expression
detected in tet-APP singly transgenic mice (Figure S3). TheNeuron 68, 428–441, November 4, 2010 ª2010 Elsevier Inc. 429
Figure 2. EC-APP Mice Have Age-Depen-
dent Deficits in Spatial Learning and
Memory
(A–C) At 4 (A), 9 (B), and 13 (C) months of age, mice
of the four genotypes were trained for 3–5 days to
locate a hiddenplatform in theMWM.By 9months,
EC-APP (tTA/tet) mice showed impaired learning
relative to the other groups (p < 0.001 for geno-
type, repeated-measures ANOVA). Their learning
deficits persisted at 13 months (p < 0.01 for geno-
type, repeated-measures ANOVA).
(D–F) At each age, probe trials were conducted
24 hr after the last training session. At 4 months,
all groups showed a clear preference for the target
quadrant. At 9 months, only EC-APPmice failed to
spend significantly more time in the target quad-
rant than in the other quadrants. At 13 months,
EC-APP mice spent comparable proportions of
time in target and nontarget quadrants, whereas
the other groups still favored the target quadrant.
(G–H) Thirteen-month-old EC-APPmice have defi-
cits in a spatial reversal-learning task. After the
probe trial (F), the platform location was changed,
and mice were trained for 3 more days to the new
location (reversal phase). In contrast to the
controls, EC-APP mice did not improve their
performance during this reversal task (G)
(p < 0.0005 for effect of training day, repeated-
measures ANOVA in the control groups only).
Distances to the new target location were shorter
in the last than the first training sessions in the
controls, but not in EC-APP mice (H). *p < 0.05,
**p < 0.005, ***p < 0.0005 versus the average
percent time spent in nontarget quadrants by
t test (D–F) or versus the first session by t test
(H); n = 10–13 mice/group. Values are mean ±
SEM.
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Transsynaptic Effects of APP/Abretrosplenial/posterior cingulate cortex (RC), which also showed
some immunostaining for mutant APP (Figure 1B), had 36% of
the expression levels in the EC (Figure 1F).
In situ hybridization with an oligonucleotide probe that specif-
ically recognizes APP mRNA encoding the human Ab domain
confirmed that the pattern of transgene-derived APP mRNA
expression matched the immunostaining pattern obtained with
the anti-human Ab antibody 6E10 (Figure S4). Transgene expres-
sion in the EC was higher in EC-APP mice than in hAPP-J20
mice, whose transgene expression levels were highest in the
DG (Figures S1C, S1D, and S4C).
Expression of Mutant APP Predominantly in the EC
Impairs Spatial Learning and Memory
Spatial learning and memory were tested in the Morris water
maze (MWM). At different ages, mice were trained over 5
consecutive days to navigate to a hidden platform using spatial
cues outside the maze. At 4 months, EC-APP (tTA/tet) mice
and controls (NTG, tTA, and tet-APP) did not differ in their ability
to learn this task, as reflected in the total distance covered
(Figure 2A) to reach the target platform. EC-APP mice displayed
a trend toward delayed acquisition in the first 2 days of training at
4 months and at 9 months were significantly impaired relative to
all control groups (Figure 2B). Mice were trained in the water430 Neuron 68, 428–441, November 4, 2010 ª2010 Elsevier Inc.maze once more at 13 months of age for 3 days; EC-APP mice
continued to have spatial learning deficits (Figure 2C). Latency
to reach the target platform revealed similar differences among
groups (data not shown). Swim speeds during hidden platform
training were not different among the groups of mice, and all
groups performed equally well in the cued version of the task
(data not shown).
The target platform was removed 24 hr after the last day of
hidden training to assess memory retention at each age. At
4 months, all groups spent more time searching in the target
quadrant (where the platform had been located) than in the other
quadrants, indicating good memory retention (Figure 2D). At
9 months, all control groups, but not EC-APP mice, showed
a significant preference for the target quadrant (Figure 2E). By
13 months, the control groups still favored the target quadrant,
whereas EC-APP mice showed no preference for the target
quadrant, indicating very poor spatial memory (Figure 2F).
Next, we analyzed spatial reversal learning in 13-month-old
mice. For this test, the target platform was moved to a new loca-
tion 24 hr after the probe trial that followed the initial hidden plat-
form training. Mice were trained to find this new location for 3
consecutive days. Over time, all control groups, but not EC-APP
mice, showed significant improvements (Figure 2G). EC-APP
mice were the only group that did not swim shorter distances
Figure 3. EC-APP Mice Show Abnormal Phenotypes in the Elevated Plus Maze and Y-Maze
(A–C) Percent time spent in open arms of an elevated plus maze was recorded over 5 min. At all ages, EC-APP (tTA/tet) mice spent more time in open arms than
control groups. *p < 0.05 versus all other groups by ANOVA and Tukey test.
(D) All groups spent less time in open arms during subsequent tests. p < 0.0001 for effects of genotype and age, two-way ANOVA.
(E–G) EC-APP mice are hyperactive in the Y-maze. Total arm entries were monitored over 6 min at 9 (E) and 13 (F) months. Compared with controls, EC-APP
(tTA/tet) mice showed a trend toward increased activity at 9 months and clear hyperactivity at 13 months. *p < 0.05 versus all other groups, ANOVA and
Newman-Keuls post hoc test. None of the groups showed habituation in Y-maze activity during the second exposure (G). p < 0.05 for genotype only, two-
way ANOVA. n = 10–13 mice/group. Values are mean ± SEM.
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retention deficits in the initial component of water maze testing
(Figures 2C and 2F) complicate the interpretation of this
reversal-learning deficit. However, the downward slope of their
first learning curves suggests that EC-APP mice learned this
task initially, albeit less well than the control groups (Figure 2C,
p = 0.06, ANOVA effect of time) but could not learn in the reversal
paradigm.
Expression of Mutant APP Predominantly in the EC
Causes Additional Behavioral Abnormalities
Decreased time spent in the open arms of an elevated plus maze
is a measure of increased anxiety (Belzung and Griebel, 2001).
Several lines of hAPP transgenic mice spend more time in the
open arms than NTG controls, suggesting lower levels of anxiety
or disinhibition (Cheng et al., 2007; Chin et al., 2005; Harris et al.,
2010; Ognibene et al., 2005). EC-APP mice also spent signifi-
cantly more time in the open arms than the control groups at
all ages (Figures 3A–3C). All groups showed some habituation
to the elevated plus maze with repeated testing (Figure 3D).
Different lines of hAPP transgenic mice also show hyperac-
tivity in several arenas, including the open field and Y-maze
(Chin et al., 2005; Kobayashi and Chen, 2005; Roberson
et al., 2007). At 9 months, EC-APP mice showed a trend toward
increased total activity in the Y-maze (Figure 3E) and by
13 months were clearly hyperactive compared to controls(Figure 3F). There was no habituation to repeated Y-maze testing
in any group (Figure 3G). EC-APP mice were not impaired in the
working memory component of the Y-maze (data not shown).
Unlike transgenic lines with widespread hAPP expression, EC-
APP mice showed no alterations in locomotor activity in the
open field at any age (Figure S5).
Expression of Mutant APP Predominantly in the EC
Elicits Alterations in Calcium- and Synaptic
Activity-Related Proteins in the DG
Previously, we identified strong correlations between learning
and memory deficits and depletions of calbindin-D28K and Fos
in GCs of the DG in hAPP-J20 mice (Palop et al., 2003). In addi-
tion, DG GCs of hAPP-J20 mice ectopically expressed neuro-
peptide Y (NPY) in the mossy fiber pathway to CA3 (Palop
et al., 2007). NPY levels were also increased in the DGmolecular
layer, likely a result of enhanced expression by interneurons
(Palop et al., 2007). Most of these DG-specific molecular alter-
ations are probably compensatory responses to Ab-induced
aberrant network activity (Palop et al., 2007).
To determine whether alterations in these proteins are caused
by APP/Ab expression in the EC, we measured their levels in the
DG of two groups of EC-APP mice (Figure 4): 6-month-old naive
mice that had never been tested behaviorally and mice that were
tested at 4, 9, and 13 months. Although EC-APP mice had no
transgene-derived APP in DG GCs (Figure 1), they had lowerNeuron 68, 428–441, November 4, 2010 ª2010 Elsevier Inc. 431
Figure 4. EC-APP Mice Have Abnormalities in Synaptic Activity-Related Proteins in the DG
(A–F) Representative coronal sections of theDG from 6-month-old NTG and EC-APP (tTA/tet) mice (A, C, and E) and quantitative results from 6- and 13-month-old
mice (B, D, and F). Brain sections from mice of all four genotypes were immunostained for calbindin, Fos, or NPY and quantified by densitometry or cell counts.
ANOVA revealed a significant effect of genotype on all protein measures. *p < 0.05 versus all other groups or as indicated by brackets with Newman-Keuls post
hoc test. n = 14–15 mice/group (6 months) or n = 6–9 mice/group (13 months). Values are mean ± SEM.
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Transsynaptic Effects of APP/Abcalbindin levels in the molecular layer at 6 and 13 months than
age-matched controls (Figures 4A and 4B), fewer GCs express-
ing Fos at both ages (Figures 4C and 4D), and a subtle but signif-
icant increase in NPY expression in mossy fibers (Figures 4E
and 4F). NPY expression in the molecular layer of the DG was
unchanged (data not shown), suggesting that expression of
APP/Ab in the EC and perforant pathway selectively affects
GCs but not interneurons in the DG.
Expression of Mutant APP Predominantly in the EC
Induces Abnormal Network Excitability
EEG recordings in other lines of APP transgenic mice revealed
cortical and hippocampal epileptic activity (Minkeviciene et al.,
2009; Palop et al., 2007). Since EC-APP mice displayed several
molecular changes in the DG that indicate such network
alterations (Figure 4) (Palop et al., 2003, 2007), we hypothesized
that they would also have periods of aberrant excitatory neuronal
activity. To test this hypothesis, we used video and EEG
recordings to monitor EC-APP and control groups of mice at
4–5 months of age over 24 hr. Bilateral recording electrodes
over the parietal cortex (PC) revealed very few or no sharp
wave discharges (SWDs) in control mice (Figures 5A–5C and 5F)
and an average of 30 SWDs per hour in EC-APP mice (Figures
5D–5F). No seizures occurred. Thus, EC-APP mice have wide-
spread cortical network alterations, even though mutant APP432 Neuron 68, 428–441, November 4, 2010 ª2010 Elsevier Inc.expression is restricted primarily to the EC. After the recordings,
we confirmed that the mice had no Ab deposition in the PC (data
not shown).
Synaptic Deficits in EC-APP Mice
Loss of synaptophysin-immunoreactive presynaptic terminals in
specific brain regions is characteristic of AD pathology and
correlates well with the degree of cognitive impairments (Sze
et al., 1997; Terry et al., 1991). Several hAPP lines, including
J20, show similar synaptic alterations (Chin et al., 2004; Galvan
et al., 2006; Hsia et al., 1999; Mucke et al., 2000; Tomiyama
et al., 2010). In 6- and 13-month-old EC-APP mice, significant
synaptophysin loss was observed in the outer molecular layer
of the DG, a terminal field of the perforant path (Figures 6A
and 6B). Compared with NTG mice, EC-APP mice also showed
a loss of synaptophysin in the stratum radiatum of CA1, where
the Schaffer collaterals terminate, but it was subtle and detect-
able only at 13 months (Figures 6C and 6D). Thus, at older
ages, some synaptic loss may occur downstream of the initial
impairment of the perforant path to GC synapse.
To determinewhether expression ofmutant APP in the EC also
impairs synaptic functions in the hippocampus, we measured
long-term potentiation (LTP) and baseline synaptic transmission
at the perforant path to GC synapses and at the Schaffer
collateral synapses in CA1. hAPP-J20 mice show distinct
Figure 5. Epileptiform Activity in Parietal
Cortex of EC-APP Mice
(A–C) Bilateral EEG recordings were performed in
4- to 5-month-old mice of all four genotypes for
24 hr. Representative traces from controls show
normal EEG activity with no or very infrequent
sharp wave discharges (SWDs).
(D) In contrast, EC-APP (tTA/tet) mice displayed
frequent SWDs.
(E) The gray area in (D) was magnified to reveal
waveforms of spike discharges in EC-APP mice.
(F) Quantification of total SWDs per hour revealed
a significantly greater frequency of SWDs in
EC-APP mice than in all other groups. p < 0.0005
for genotype by ANOVA and *p < 0.05 versus
all other groups by Tukey post hoc test. n =
4–7 mice/group. L, left PC; R, right PC. Values
are mean ± SEM. Scale bars: (A), 10 s and
500 mV; (E), 0.5 s and 100 mV.
Neuron
Transsynaptic Effects of APP/Abelectrophysiological abnormalities at different synapses (Palop
et al., 2007). Specifically, LTP is impaired and baseline synaptic
transmission is normal in the perforant path to GC synapses,
whereas baseline synaptic transmission is impaired and LTP isFigure 6. Synaptic Deficits in EC-APP Mice
(A–D) Percent area of sections occupied by synaptophysin-immunoreactive struc
(A and B) and 13 (C and D) months of age. At both ages, synaptophysin levels we
Genotype affected synaptophysin levels in CA1 at 13 but not 6 months (B and D).
cated by the bracket (Tukey post hoc test).
(E–H) Electrophysiological recordings were obtained in acute hippocampal slices
in EC-APPmice was normal at the perforant path-GC synapse in the DG (E, n = 6–
synapse (F, p < 0.05, two-way repeated-measures ANOVA, n = 9–10 slices from 3
DG of EC-APP mice relative to controls (G, p < 0.05, repeated-measures ANOV
Schaffer collateral-CA1 synapse (H, n = 3–4 slices from 2–3 mice/genotype). Allnormal in Schaffer collateral synapses onto CA1 pyramidal cells.
Recording of extracellular field excitatory postsynaptic potential
(fEPSP) revealed no abnormalities in these measures at either
synapse in 6-month-old EC-APP mice (data not shown).tures in the outer molecular layer of the DG and stratum radiatum of CA1 at 6
re lower in the DG of EC-APP (tTA/tet) mice than in all control groups (A and C).
n = 6–9 mice/group. *p < 0.05, ***p < 0.0005 versus all other groups or as indi-
from 13- to 14-month-old EC-APP and NTGmice. The input-output relationship
7 slices from three mice/genotype), but impaired at the Schaffer collateral-CA1
–5 mice/genotype). LTP was impaired at the perforant path-GC synapse in the
A from 50 to 60 min, n = 3–4 slices from three mice/genotype), but not at the
values shown are mean ± SEM.
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Figure 7. Ab Levels and Plaque Distribution
in Interconnected Brain Regions of Young
and Older EC-APP Mice
(A–C) Soluble levels of Ab1-x and Ab1-42 were
measured before plaque formation in EC (A), DG
(B), and CA1 (C) by ELISA in 3-month-old EC-
APP (tTA/tet) mice and age-matched hAPP-J20
mice. Levels of Ab1-x and Ab1-42 in EC and
Ab1-x in DG were comparable in EC-APP mice
and hAPP-J20 mice. Levels of Ab1-x and Ab1-42
in CA1 and of Ab1-42 in DG were lower in EC-
APP mice than in hAPP-J20 mice. n = 3–4 mice/
genotype. *p < 0.05, **p < 0.005, ***p < 0.0005
versus hAPP-J20 by t test.
(D–F) Immunostaining for Abwith the 3D6 antibody
revealed an age-dependent increase in Ab deposi-
tion in the EC, DG, CA, RC, and PC of EC-APP
mice. Representative coronal (left) and horizontal
(middle) brain sections for each age are shown in
(D) and (E). Percent area covered by 3D6-immuno-
reactive Ab deposits was quantified to determine
plaque loads. Horizontal sections were used for
EC and coronal sections for DG, CA, RC, and
PC. Numbers of mice analyzed: at 6 months, n =
15 (coronal; DG, CA, RC, PC) and 9 (horizontal;
EC); at 13 months, n = 7 (coronal) and 4 (hori-
zontal). n.s., not significant, **p < 0.005, ***p <
0.0005 EC versus DG, CA, and PC; #p < 0.05,
###p < 0.0005 RC versus DG, CA, and PC by
ANOVA and Tukey post hoc test. Values are
mean ± SEM. Higher-magnification images from
13-month-old mice showing plaque deposition
throughout the EC are shown (F, left). In the DG
(F, middle and right), plaques were localized
predominantly in the terminal fields of perforant
pathway axons from the EC: stratum lacunosum
moleculare (slm) and ml.
(G and H) Small oligomeric forms of Ab were
detected by immunoprecipitation/western blotting
in different brain regions of 13-month-old EC-APP
and hAPP-J20 mice. Ab dimers were present in
all brain regions analyzed; the highest levels
were in the EC of EC-APP mice. Syn., synthetic.
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Transsynaptic Effects of APP/AbTherefore, wemeasured LTP and baseline synaptic transmission
in mice with well-developed cognitive deficits. We first tested
a new cohort of 13- to 14-month-old NTG and EC-APP mice in
the MWM and replicated the learning and memory deficits
described in Figure 2 (data not shown). In EC-APPmicewith veri-
fied spatial learning deficits, baseline synaptic transmission
strength was reduced only at the Schaffer collateral to CA1
synapses (Figures 6E and 6F). As in hAPP-J20 mice, LTP was
depressed at the perforant path to GC synapses in EC-APP434 Neuron 68, 428–441, November 4, 2010 ª2010 Elsevier Inc.mice relative to NTG controls, but no
LTP deficits were identified in CA1
(Figures 6G and 6H).
Ab Deposition in EC-APP Mice
Molecular alterations in DG GCs of EC-
APPmice could result from direct actions
of presynaptically released Ab on post-
synaptic membranes or from functionalchanges in afferent input from perforant path axons caused by
Ab in EC neurons. To address these nonexclusive possibilities,
we determined whether Ab was present not only in the EC, but
also in terminal projection zones of EC layer II/III neurons, which
overexpress APP/Ab in EC-APPmice. Soluble Abwasmeasured
by ELISA in microdissected brain regions of young EC-APPmice
before plaque deposition and compared to hAPP-J20 mice.
EC-APP mice had high levels of Ab1-x and Ab1-42 in the EC
(Figure 7A) and relatively high levels of Ab1-x in the DG
Figure 8. Inhibiting g-Secretase Cleavage to Reduce Ab Production
Normalizes EPM Behavior in 4-Month-Old EC-APP Mice
(A) Mice were injected once a day with LY-411575 (3 mg/kg) or vehicle on 2
consecutive days and tested in the EPM 6–8 hr after the second injection.
Vehicle-treated EC-APP (tTA/tet) mice spent more time in the open arms
than vehicle-treated NTG mice. LY-411575 treatment significantly reduced
the time EC-APP mice spent in the open arms to levels in vehicle-treated
NTG controls. n = 5–7 mice/group. p < 0.005 for the interaction effect between
genotype and treatment by two-way ANOVA, *p < 0.05 versus NTG+ vehicle or
as indicated by bracket (one-way ANOVA followed by Tukey post hoc test).
(B) APP CTFs in the EC of EC-APP mice were measured by western blotting
and quantified by densitometry. Inhibition of g-secretase cleavage increased
CTF levels. n = 5–7 mice/group. **p < 0.005 versus vehicle by t test. Values
are mean ± SEM.
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much higher APP levels in the DG (Figures S1C and S1D). In
contrast, levels of Ab1-42 in the DG (Figure 7B) and of Ab1-x
and Ab1-42 in the CA1 region (Figure 7C) were lower in EC-
APP mice than in hAPP-J20 mice. EC-APP mice had higher
levels of soluble Ab in EC and DG, but not in CA regions (Figures
S3C–S3E), than singly transgenic tet-APP mice. Therefore, the
low levels of Ab in the CA of young EC-APP mice were likely
caused by leakiness of the tet promoter.
At 6 months of age, EC-APP mice had Ab-immunoreactive
deposits in the EC and the RC, but not in other cortical areas
or in the DG (Figure 7D). By 13 months, Ab deposition had
increased markedly in the EC and RC and in the DG and CA
regions of the hippocampus. Ab deposition also increased in
the PC, which is near the RC (Figures 7E and 7F). The extent of
Ab deposition in the EC and RC was comparable and signifi-
cantly higher than in other regions analyzed. Ab deposits were
found in all layers in the EC (Figure 7F, left) and primarily in per-
forant pathway terminal fields in the hippocampus: the stratum
lacunosum moleculare (Figure 7F, middle) and the molecular
layer of the DG (Figure 7F, right). Ab deposits were minimal or
absent in the hilus and mossy fiber pathway. In contrast,
hAPP-J20 mice had particularly prominent deposits in the inner
molecular layer of the DG and mossy fiber pathway in CA3
(Figure S6). This pattern of deposition in EC-APP mice strongly
suggests presynaptic release of Ab, as opposed to simple diffu-
sion from the EC.
Finally, we measured the levels of smaller, potentially more
toxic oligomeric Ab assemblies in 13-month-old EC-APP mice
by immunoprecipitation and western blotting. The intensity of
bands corresponding to Ab dimers wasmost intense in EC, inter-
mediate in DG, and lowest in CA1 (Figures 7G and 7H). Ab dimer
levels in DG were similar in EC-APP and hAPP-J20 mice
(Figure 7G), but Ab monomer levels in DG and CA1 were lower
in EC-APP mice.
Reducing Ab Production by g-Secretase Inhibition
Reverses an Abnormal Behavior in EC-APP Mice
Much evidence suggests that Ab is the primary mediator of AD-
related molecular and behavioral abnormalities in APP trans-
genic mice and humans (Harris et al., 2010; Palop et al.,
2003, 2007; Sun et al., 2008; Tanzi, 2005; Walsh and Selkoe,
2004). However, other APP metabolites or the holoprotein itself
could also have a role. Therefore, we analyzed the behavioral
effects of LY-411575, a g-secretase inhibitor (GSI) that rapidly
reduces tissue and interstitial fluid levels of Ab in APP trans-
genic mice (Abramowski et al., 2008; Cirrito et al., 2003; Lanz
et al., 2004). Four-month-old EC-APP and NTG mice were
treated once daily for 2 days and tested in the elevated plus
maze because it is a quick and sensitive test of dysfunction in
this line (Figures 3 and 8A), and chronic treatment with this
GSI causes mice to become too ill for long-term behavioral
experiments such as the MWM (L.V. and J.J.P., unpublished
data). LY-411575-treated EC-APP mice spent significantly
less time in the open arms than vehicle-treated EC-APP mice,
normalizing their behavior in this test as compared with
vehicle-treated NTG controls (Figure 8A). There was a trend
toward increased open arm time in GSI-treated NTG miceversus vehicle-treated NTG controls, but this difference was
not statistically significant.
We verified that LY-411575 was active by measuring
C-terminal fragments (CTFs) in the EC, which increase when
g-secretase is inhibited (Abramowski et al., 2008; Cirrito et al.,
2003). Ten hours after the second injection of LY-411575, CTF
levels were significantly increased (Figure 8B). Therefore, it is
very unlikely that b-secretase-cleaved CTFs such as C99
underlie this behavioral abnormality in APP transgenic mice.
Measurements of Ab levels were not used as a reporter for
LY-411575 activity because mice at this age already have Ab
deposition in the EC, and existing plaques are not reduced by
LY-411575 (Garcia-Alloza et al., 2009).
DISCUSSION
It is not known how EC dysfunction contributes to cognitive
decline in AD or whether early vulnerability of the EC initiates
the spread of dysfunction through interconnected neural
networks. To address these questions, we studied transgenic
mice with spatially restricted overexpression of mutant APP
primarily in superficial-layer neurons of the EC. We found age-
dependent deficits in learning and memory, other behavioral
alterations, and aberrant synchronization in distant cortical
networks in these mice. We also found that Ab-induced molec-
ular and functional impairments can cross synapses, progress-
ing with time/aging initially from EC neurons to GCs in the DG
and then to pyramidal neurons in CA1. Our data directly support
the hypothesis that AD-related neuronal dysfunction is propa-
gated through synaptically connected neural networks, with
the EC as an important hub region of early vulnerability.Neuron 68, 428–441, November 4, 2010 ª2010 Elsevier Inc. 435
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In AD, PiB-PET and fMRI studies demonstrated extensive Ab
deposition in the ‘‘default mode network’’ (DMN), a group of
brain regions with correlative activity that deactivate during
cognitive tasks (Buckner et al., 2005; Sperling et al., 2009). A
major hub of the DMN is the posterior cingulate cortex, which
includes the RC in humans and nonhuman primates (Vann
et al., 2009). We also found extensive Ab deposition in the RC
of EC-APP mice, which was not different from that in the EC,
even though APP overexpression was much lower in the RC
than the EC (Figure 1). hAPP-J20 mice also had substantial Ab
deposition in the RC (Figure S6).
The RC has reciprocal connections to the medial EC (Jones
and Witter, 2007; Van Groen and Wyss, 2003; Wyss and Van
Groen, 1992), but inputs from the medial EC originate in neurons
of deeper layers (Insausti et al., 1997), not in neuronsof superficial
layers, which express mutant APP in the EC-APP mouse model.
Thus, the EC is an unlikely source of Ab deposition in the RC of
these mice. EC-APP mice also express mutant APP in the para-
hippocampal pre- and parasubiculum, which have reciprocal
connections to the RC (Jones and Witter, 2007; Van Groen and
Wyss, 2003; Wyss and Van Groen, 1992). Therefore, presynaptic
terminals from these regions may release Ab into the RC. The RC
also receives hippocampal input directly from the subiculum, but
does not share direct projections with the DG, CA1, or CA3, at
least in rats (Jones and Witter, 2007; Van Groen and Wyss,
2003; Wyss and Van Groen, 1992). In light of these anatomical
connections, neurons of the RC could also be affected indirectly
by Ab-induced alterations in the activity of the EC-hippocampal
network. Indeed, lesions of the hippocampus reduce imme-
diate-early gene expression in the RC (Albasser et al., 2007).
In conjunction with the hippocampus, the RC is important in
spatial navigation, learning, and memory (Vann et al., 2009).
Therefore, accumulation of pathogenic Ab assemblies in the
RC could contribute directly to deficits in these functions. Impor-
tantly, the EC, RC, and hippocampus are part of a broader
network regulating spatial learning andmemory, and dysfunction
in one region is not necessarily independent of dysfunction in the
others.
Transsynaptic Effects of Ab
Lesions of the EC or transecting the perforant pathway reduces
Ab deposition in the DG of transgenic APP/PS1 mice (Lazarov
et al., 2002; Sheng et al., 2002). These studies support the
hypothesis that the EC is a primary source of Ab in the hippo-
campus. However, since neuronal activity increases Ab produc-
tion (Cirrito et al., 2005, 2008; Kamenetz et al., 2003), reduced Ab
deposition in the DG after perforant pathway lesions might also
result from decreased stimulation of GCs in the DG and
commensurate decreases in their activity and Ab production.
Our data directly demonstrate that perforant pathway axons
are an important source of Ab in the DG, as APP expression in
EC-APP mice was seen in the EC and perforant path but not in
DG GCs. These findings are consistent with data suggesting
that presynaptic terminals are a key site for Ab production and
release (Buxbaum et al., 1998; Wei et al., 2010).
Ab released from perforant pathway terminals may act directly
on postsynaptic cells and alter their functions, particularly when436 Neuron 68, 428–441, November 4, 2010 ª2010 Elsevier Inc.aggregated in oligomeric assemblies. Alternatively, Ab may
affect the presynaptic terminals themselves, for instance, by
altering the release probability of synaptic vesicles (Abramov
et al., 2009) and thus changing downstream signaling pathways
in the postsynaptic GCs. In addition, Ab synthesized and
released from cell bodies or dendrites of EC neurons may act
on these very cells, altering afferent input to the DG. These possi-
bilities are not mutually exclusive and deserve to be explored in
future studies. The reduction in synaptic activity-related proteins
in DG GCs probably reflects altered network properties and
could have detrimental effects on hippocampal function. For
example, reducing calbindin or Fos levels in normal rats or
mice causes deficits in spatial learning (He et al., 2002; Molinari
et al., 1996); decreased levels of synaptophysin suggest loss or
impairment of presynaptic terminals that could disrupt commu-
nication between the EC and DG (Hsia et al., 1999; Scheff and
Price, 2003; Terry et al., 1991).
Regardless of whether Ab exerts itsmain effects in the EC, DG,
or both, the progression of molecular and functional synaptic
alterations from EC neurons to DG neurons and CA1 neurons
supports the hypothesis that AD progresses through synaptically
connected neural networks and that this process could be trig-
gered by Ab (Braak et al., 2006; Buckner et al., 2005; Palop
and Mucke, 2010; Seeley et al., 2009; Sperling et al., 2009).
The propagation of functional alterations into the DG and CA1
is likely to be very rapid, whereas molecular and structural
changes may require more time to develop, as suggested by
the delayed decrease in synaptophysin levels in CA1. Whether
APP/Ab expression in the EC exerts indirect effects on DG target
cells in the hilus or CA3 region remains to be determined.
Similarities between hippocampal synaptic deficits in hAPP-
J20 mice with high levels of Ab in DG and CA1 and in EC-APP
mice with lower levels of Ab in these regions suggest two possi-
bilities. First, the deficitsmay emergewhenever Ab levels exceed
a threshold. In support of this possibility, synaptic transmission
deficits in CA1 are also present in hAPP-J9 mice, whose hippo-
campal hAPP/Ab levels are half those in hAPP-J20 mice (Hsia
et al., 1999; Mucke et al., 2000). Ab levels in the DG of EC-APP
mice (i.e., Ab released from EC-derived terminals) are 70% of
those in hAPP-J20 mice (Figure 7B). Second, the deficits in the
hippocampus of both lines may be caused indirectly by Ab-
induced abnormalities in the activity of EC neurons. These possi-
bilities are not mutually exclusive. The detection of epileptiform
activity in the PC of EC-APP mice suggests that APP/Ab in one
area may impact other brain regions by causing aberrant activity
patterns that rapidly spread through interconnected neural
networks.
Ab is released from presynaptic terminals (Wei et al., 2010)
and, in our opinion, is the likeliest APP metabolite to mediate
transsynaptic spread of AD. The caspase-generated APP-C31
fragment (Gervais et al., 1999; Weidemann et al., 1999) does
not play amajor role in the development of AD-related abnormal-
ities in APP transgenic mice (Harris et al., 2010). Treatment with
LY-411575, a GSI that decreases soluble Ab levels and
increases CTF levels (Figure 8B) (Abramowski et al., 2008; Cirrito
et al., 2003; Lanz et al., 2004), reversed behavioral abnormalities
in EC-APP mice. This finding supports a critical role of Ab and
makes it very unlikely that the abnormal behavior of EC-APP
Neuron
Transsynaptic Effects of APP/Abmice was caused by b-secretase-cleaved CTFs such as C99.
However, it does not exclude potential contributions from all
other APP metabolites that might have copathogenic effects,
including N-APP (Nikolaev et al., 2009) and AICD (Ghosal et al.,
2009).
Role of the EC in Cognitive and Noncognitive Behaviors
Although the relationship between cognitive and behavioral
abnormalities in APP transgenic mice and humans with AD is
a matter of debate, we previously identified prominent naviga-
tional and hippocampal deficits in both the models and in AD
patients (deIpolyi et al., 2007, 2008). In the current study,
increasing Ab production by EC neurons and perhaps also by
RC neurons caused age-dependent deficits in spatial learning
and memory, suggesting that impairments of those neurons or
their target regions are critical for the functional deficits. Indeed,
the EC and its intact perforant path connections to the hippo-
campus are critical for learning, retrieval, and/or consolidation
of spatial memory (Kirkby and Higgins, 1998; Ramirez et al.,
2007; Remondes and Schuman, 2004; Steffenach et al., 2005).
Ab-induced dysfunction of the RC could also contribute to these
behavioral deficits.
The reversal-learning paradigm (Figures 2G and 2H) provides
evidence for a specific role of the EC and its connections in flex-
ible learning of a new spatial task. This task requires mice to
discard a previously learned target location and acquire a new
one. EC-APP mice had difficulties learning the new platform
location. The learning deficits in the initial component of the
MWM complicate the interpretation of this phenotype as solely
a reversal-learning deficit. However, while EC-APP mice did
not show significant memory retention in the first task, they
showed some evidence of learning to navigate to the hidden
platform initially (Figure 2C, p = 0.06, one-way ANOVA effect of
time). The lack of any improvement in the reversal-learning
task suggests an additional impairment in flexibility or reflects
other behavioral disturbances. The EC-APP model could help
elucidate the roles of the EC and perforant pathway projections
in this process.
Mice of the APP transgenic line PDAPP 109 were also
impaired in a related behavioral task (Chen et al., 2000). Neither
the anatomical regions nor the molecular mechanisms under-
lying the required flexibility have been elucidated, although adult
neurogenesis in the DG is important for spatial reversal learning
(Garthe et al., 2009) and is altered in APP transgenic mice
(Donovan et al., 2006; Lo´pez-Toledano and Shelanski, 2007;
Sun et al., 2009), most likely because Ab causes an imbalance
in excitatory and inhibitory inputs to newborn GCs (Sun et al.,
2009).
EC-APP mice also behaved abnormally in the elevated plus
maze and were hyperactive in the Y-maze. Time spent in the
open arms of an elevated plus maze is usually considered
a measure of anxiety, and with this interpretation, several lines
of hAPP mice appear to be less anxious (Cheng et al., 2007;
Chin et al., 2005; Harris et al., 2010; Ognibene et al., 2005).
Increased time in the open arms could also reflect disinhibition
in APP transgenic mice. The amygdala, regarded as the anatom-
ical substrate of fear- and anxiety-related behaviors, receives
direct input from the EC. However, this input is from neurons indeep cortical layers (McDonald, 1998), which do not overex-
pressmutant APP in the EC-APPmice. The ventral hippocampus
is more specifically associated with performance in the elevated
plus maze than the amygdala (Bannerman et al., 2004) and
receives direct input from the superficial-layer neurons overex-
pressing mutant APP in EC-APP mice. Like EC-APP mice, rats
with lesions of the ventral hippocampus or severed perforant
pathway projections to the ventral hippocampus spent more
time in the open arms of an elevated plus maze (Kjelstrup
et al., 2002; Steffenach et al., 2005). Our data further support
a role for the EC and its hippocampal connections in this behav-
ioral phenotype, although the amygdala could still be involved in
a more indirect fashion.
The hippocampus may be one of many brain regions that can
regulate locomotor activity (Bast and Feldon, 2003). Unlike APP
transgenic mice with widespread transgene expression, which
are hyperactive in both the open field and the Y-maze (Chin
et al., 2005; Kobayashi and Chen, 2005; Roberson et al.,
2007), EC-APP mice were hyperactive only in the Y-maze. Why
EC-APP mice performed differently in these tests is unclear.
One possibility is that these tests measure different components
of locomotor activity control. Indeed, all groups of mice habitu-
ated to the open field but not to the Y-maze. Activity in the
open field may be related to hippocampus-dependent informa-
tion gathering about a novel environment, whereas locomotor
activity in the Y-maze may reflect a different process.
Therapeutic Implications
Without effective drug treatments for AD, interest in alternative
approaches, such as gene therapy and stem cells, is increasing
(Spencer et al., 2007; Tuszynski et al., 2005). However, the
success of these approaches may depend on whether AD
affects multiple brain regions in parallel or in sequence. In the
latter case, AD progression might be stopped by targeting the
specific region in which the disease originates, which would be
simpler than targeting multiple regions. Thus, if dysfunction in
the EC leads to the propagation of AD across synapses
throughout a neural network, early interference, specifically in
the EC, might be of therapeutic benefit, perhaps halting disease
progression. Indeed, BDNF introduced into the EC was trans-
ported into the hippocampus and rescued spatial memory func-
tions in APP transgenic mice (Nagahara et al., 2009). Tau and Ab
may also share features with prions, including the ability to
propagate pathological protein aggregation, perhaps through
synaptic connections (Clavaguera et al., 2009; Eisele et al.,
2009; Frost and Diamond, 2010). It will be interesting to assess
the effects of selective EC expression of tau and other factors
on the development and propagation of AD-related pathologies.
EXPERIMENTAL PROCEDURES
Animals
Neuropsin-tTA heterozygous transgenic mice (Yasuda and Mayford, 2006)
were crossed with tet-APP heterozygous transgenic mice (Jankowsky et al.,
2005) to generate four genotypes: tTA/tet doubly transgenic (EC-APP) mice,
tTA or tet singly transgenic mice, and NTG controls. Mice did not receive
doxycycline so as to maintain expression of the tet-APP transgene. Neuro-
psin-tTA mice on the C57BL/6 background were provided by Mark Mayford.
Tet-APP mice were on a C57BL/6-C3H background (Jackson Laboratory,Neuron 68, 428–441, November 4, 2010 ª2010 Elsevier Inc. 437
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Transsynaptic Effects of APP/Abstock no. 006004) or on a C57BL/6 background (Jackson Laboratory, stock
no. 007049). See Supplemental Experimental Procedures for more detail on
strain background. All analyses were done in gender-balanced groups. Exper-
imenters were blinded to genotype and treatment. The Institutional Animal
Care and Use Committee of the University of California, San Francisco
approved all experiments.
Behavioral Tests
One cohort of mice was evaluated at 4, 9, and 13months of age in the elevated
plus maze and MWM. The same mice were analyzed in the Y-maze at 9 and
13 months.
Elevated Plus Maze
The elevated plus maze consisted of two open (without walls) and two
enclosed (with walls) arms elevated 63 cm above the ground (Hamilton-
Kinder). Mice were allowed to habituate in the testing room under dim light
for 1 hr before testing. During testing, mice were placed at the junction
between the open and closed arms of the plus maze and allowed to explore
for 5min. Themazewas cleanedwith 70%alcohol after testing of eachmouse.
Total distance traveled and time spent in the open and closed arms were
calculated based on infrared photobeam breaks.
Y-Maze
The apparatus consisted of three symmetrical arms in a Y shape. Before
testing, mice were transferred to the testing room and acclimated for at least
1 hr. During testing, each mouse was placed in a starting arm facing the wall.
Arm entries were recorded for 6 min, divided into six 1 min intervals. The maze
was cleaned with 70% alcohol between testing of each mouse. Spontaneous
alternations and total activity were calculated.
Morris Water Maze
Mice were trained in the MWM for 3–5 days as described, with modifications
(Harris et al., 2010). See Supplemental Experimental Procedures for details.
At 13 months of age, mice also underwent reversal training, where the target
platform was moved to the opposite quadrant of the MWM pool after the initial
hidden training sessions were completed. Behavior was recorded with a video
tracking system (Noldus). Escape latencies, distance traveled, swim paths,
swim speeds, percent time spent in each quadrant, and platform crossings
were recorded for subsequent analysis. Thigmotaxis was monitored during
the last trial of hidden platform training in both initial acquisition and reversal
learning. No mice exhibited thigmotaxis in these experiments. Floating
behavior was also monitored during training. Only one mouse (a singly tTA
transgenic at 13 months) exhibited floating and was removed from the
analysis.
g-Secretase Inhibitor Treatment
NTG and EC-APP mice were injected subcutaneously once daily for 2 days
with 3 mg/kg LY-411575 (a gift of J. Tung and the Myelin Repair Foundation)
or vehicle (corn oil) and tested in the elevated plus maze 6–8 hr after the last
injection. All mice were sacrificed directly after the testing (approximately
10 hr from the second LY-411575 injection). Brains were harvested and frozen
for ELISA and western blot analyses.
Immunohistochemistry
Tissue was prepared as described (Harris et al., 2010). Primary antibodies
were rabbit anti-calbindin (1:20,000; Swant), rabbit anti-Fos (1:10,000; Ab-5,
Oncogene), rabbit anti-NPY (1:8000; Immunostar), mouse biotinylated anti-
Ab (1:400; 3D6, Elan Pharmaceuticals), mouse anti-APP/Ab (1:10,000; clone
6E10; Covance), mouse anti-hAPP (1:2000, clone 8E5, Elan Pharmaceuticals),
and mouse anti-synaptophysin (1:1000; Boehringer Mannheim). Sections
labeled with anti-synaptophysin were incubated with FITC-conjugated horse
anti-mouse IgG secondary antibody (1:75; Vector). Binding of other primary
antibodies was detected with biotinylated donkey anti-rabbit or anti-mouse
(1:1000; Jackson Immunoresearch), followed by incubation with avidin-biotin
complex (Vector). Fos, calbindin, NPY, synaptophysin, and Ab immunoreactiv-
ities were quantified in a behaviorally naive cohort of mice at 6 months and in438 Neuron 68, 428–441, November 4, 2010 ª2010 Elsevier Inc.mice that underwent behavioral testing at 13 months of age. Quantifications
were performed as described (Chin et al., 2004; Palop et al., 2003, 2007).
Ab ELISAs and Immunoblotting
For Ab and APP measurements in specific regions, brain tissues were micro-
dissected into DG, EC, CA, and RC. To obtain DG samples, the GC andmolec-
ular layers were microdissected away from the hilar region and CA3. For Ab
ELISAs, samples were snap-frozen and homogenized in 5 M guanidine buffer.
Ab1-x (approximates total Ab) and Ab1-42 were quantified as described
(Johnson-Wood et al., 1997; Mucke et al., 2000). Low-molecular-weight olig-
omeric Ab species were detected by immunoprecipitation and western blot-
ting. APP levels were assessed by western blotting in microdissected samples
as described (Harris et al., 2010). See Supplemental Experimental Procedures
for further details.
EEG Recordings
Mice were implanted for video EEG monitoring after anesthesia with intraper-
itoneal ketamine (75 mg/kg) andmedetomidine (1 mg/kg). Teflon-coated silver
wire electrodes (0.125 mm diameter) soldered to a multichannel electrical
connector were implanted into the subdural space over the left frontal cortex
(coordinates relative to the bregmawereM/L, ±1; A/P, ±1) and the left and right
PC (M/L, ±2, A/P,2). The left frontal cortex electrodewas used as a reference.
All EEG recordings were carried out at least 10 days after surgery on freely
moving mice in a recording chamber. EEG activity was recorded with the
Harmonie software (version 5.0b) for 24 hr. The number of SWDswas automat-
ically detected by the Gotman spike and seizure detectors (Harmonie) and
manually verified.
Electrophysiological Recordings in Acute Slices
Acute coronal slices (400 mm) were prepared from NTG and EC-APP mice at 6
and 14months of age. See Supplemental Experimental Procedures for details.
fEPSPs were recorded with glass electrodes (3 MU tip resistance) filled with
1 M NaCl and 25 mM HEPES (pH 7.3) and evoked every 20 s with a bipolar
tungsten electrode (FHC, Inc.) in the presence of 50 mM picrotoxin (Tocris).
Recordings were filtered at 2 kHz (3 dB, eight-pole Bessel), digitally sampled
at 20 kHz with a Multiclamp 700A amplifier (Molecular Devices), and acquired
with a Digidata-1322A digitizer and pClamp 9.2 software. Synaptic transmis-
sion strengths in the DG and CA1 were assessed by generating input-output
(I-O) curves for fEPSPs. Fiber volley amplitude and initial slope of the fEPSP
responses to a range of stimulation from 25 to 800 mA were recorded, and
a response curve was generated for both values. Stimulus strength was
adjusted to 30% of the maximal fEPSP response for recordings that fol-
lowed. After a 10 min stable baseline was established, LTP was induced
in CA1 by high-frequency stimulation (four 100 Hz trains of 100 stimuli every
20 s) and in DG by theta burst stimulation (ten bursts repeated ten times every
15 s; each burst consisting of four pulses at 100 Hz was repeated at 5 Hz).
Statistical Analyses
Experimenters were blinded to the genotype and treatment of mice. Statistical
analyses were conducted with GraphPad Prism version 4.0 or 5.0. Differences
between means were analyzed by two-tailed t test and one-way or two-way
ANOVA with post hoc tests as appropriate; p < 0.05 was considered
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, and six figures and can be found with this article
online at doi:10.1016/j.neuron.2010.10.020.
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